Cantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Key Points

• Cantor Fitzgerald raised Ultragenyx’s price target from $33 to $39 and maintained an “overweight” rating, implying approximately 169% upside from the reported $14.50 share price.
• Analyst sentiment remains generally positive but mixed: the stock has a consensus “Moderate Buy” rating and an average price target of $36.95, while several firms recently lowered targets or downgraded the shares.
• Ultragenyx exceeded quarterly expectations, reporting an adjusted loss of $0.90 per share versus the anticipated $1.22 loss and revenue of $214 million, up 28.5% year over year. The FDA’s approval of FAYUVI, its second gene therapy, provides an additional potential growth catalyst.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) had its price objective boosted by equities researchers at Cantor Fitzgerald from $33.00 to $39.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently has an "overweight" rating on the biopharmaceutical company's stock. Cantor Fitzgerald's price target would indicate a potential upside of 168.97% from the company's previous close.

Several other equities analysts also recently issued reports on the stock. Guggenheim decreased their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, August 4th. Robert W. Baird downgraded shares of Ultragenyx Pharmaceutical from an "outperform" rating to a "neutral" rating and reduced their price target for the stock from $40.00 to $16.00 in a research report on Thursday, September 3rd. Bank of America lowered shares of Ultragenyx Pharmaceutical from a "buy" rating to a "neutral" rating in a research note on Thursday, September 3rd. Morgan Stanley lifted their price objective on Ultragenyx Pharmaceutical from $67.00 to $74.00 and gave the stock an "overweight" rating in a report on Friday, August 21st. Finally, The Goldman Sachs Group cut their price objective on Ultragenyx Pharmaceutical from $28.00 to $19.00 and set a "neutral" rating for the company in a research note on Friday, September 4th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $36.95.

Ultragenyx Pharmaceutical Trading Up 12.6%

Shares of RARE stock opened at $14.50 on Friday. Ultragenyx Pharmaceutical has a 12-month low of $12.73 and a 12-month high of $39.89. The business's 50 day moving average is $24.26 and its two-hundred day moving average is $24.49. The company has a market capitalization of $1.43 billion, a P/E ratio of -2.48 and a beta of 0.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating analysts' consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The business had revenue of $214.00 million during the quarter, compared to analysts' expectations of $183.08 million. During the same period in the previous year, the business earned ($1.17) earnings per share. The business's revenue was up 28.5% compared to the same quarter last year. On average, research analysts predict that Ultragenyx Pharmaceutical will post -3.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently modified their holdings of the business. Versant Capital Management Inc raised its position in Ultragenyx Pharmaceutical by 662.9% during the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company's stock worth $38,000 after acquiring an additional 1,001 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Ultragenyx Pharmaceutical by 149.5% during the 2nd quarter. GAMMA Investing LLC now owns 1,919 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 1,150 shares in the last quarter. Leonteq Securities AG increased its stake in shares of Ultragenyx Pharmaceutical by 288.5% during the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 1,333 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $48,000. Finally, Parallel Advisors LLC raised its position in shares of Ultragenyx Pharmaceutical by 778.4% during the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 1,440 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: The FDA approved FAYUVI (rebisufligene etisparvovec-hopf) as the first approved treatment for pediatric Sanfilippo syndrome Type A, a fatal and progressive neurodegenerative disease with no prior treatment options. The therapy is designed to deliver a functional copy of the deficient SGSH gene. Reuters FDA approval article
• Positive Sentiment: Clinical data supported full approval: treated patients showed a 23.5-point cognitive-score advantage versus an external natural-history group, with follow-up extending nearly eight years. Ultragenyx also received a Priority Review Voucher, which could accelerate a future drug candidate’s FDA review. Ultragenyx FAYUVI approval release
• Positive Sentiment: FAYUVI is Ultragenyx’s second approved gene therapy and sixth FDA-approved product. The company expects shipments to qualified treatment centers within 30–60 days and has established its UltraCare program to help families navigate treatment and insurance access. Reports indicate a $3.95 million price, creating significant revenue potential if reimbursement and adoption are favorable. FAYUVI pricing article

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company's work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.

Ultragenyx's marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.